within Pharmacolibrary.Drugs.ATC.L;

model L04AC15
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.14 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,
    adminCount     = 1,
    Vd             = 0.00713,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Sirukumab is a human monoclonal antibody that binds to and inhibits interleukin-6 (IL-6), a cytokine involved in inflammatory processes. It was developed for the treatment of autoimmune conditions, particularly rheumatoid arthritis. Although it showed efficacy, it is not currently approved for clinical use due to safety concerns and unfavorable risk-benefit evaluation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported from phase 3 studies in adult patients with moderate-to-severe rheumatoid arthritis.</p><h4>References</h4><ol><li><p>Zhuang, Y, et al., &amp; Zhou, H (2013). Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects. <i>International journal of clinical pharmacology and therapeutics</i> 51(3) 187–199. DOI:<a href=&quot;https://doi.org/10.5414/CP201785&quot;>10.5414/CP201785</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23357841/&quot;>https://pubmed.ncbi.nlm.nih.gov/23357841</a></p></li><li><p>Xu, Z, et al., &amp; Zhou, H (2011). Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. <i>British journal of clinical pharmacology</i> 72(2) 270–281. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.2011.03964.x&quot;>10.1111/j.1365-2125.2011.03964.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21392075/&quot;>https://pubmed.ncbi.nlm.nih.gov/21392075</a></p></li><li><p>Zhuang, Y, et al., &amp; Xu, Z (2017). Absolute Bioavailability and Pharmacokinetic Comparability of Sirukumab Following Subcutaneous Administration by a Prefilled Syringe or an Autoinjector. <i>Clinical pharmacology in drug development</i> 6(6) 570–576. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.328&quot;>10.1002/cpdd.328</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28052588/&quot;>https://pubmed.ncbi.nlm.nih.gov/28052588</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AC15;
